Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.25.

XERS has been the subject of a number of analyst reports. Leerink Partners upped their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, March 7th. Craig Hallum upped their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler reissued a “neutral” rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Oppenheimer upped their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, May 9th.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $5.05 on Tuesday. Xeris Biopharma has a fifty-two week low of $2.03 and a fifty-two week high of $6.07. The stock’s fifty day moving average is $4.63 and its two-hundred day moving average is $4.05. The firm has a market capitalization of $789.74 million, a P/E ratio of -11.22 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to analysts’ expectations of $57.61 million. On average, equities analysts forecast that Xeris Biopharma will post -0.41 earnings per share for the current year.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. The trade was a 2.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.47% of the company’s stock.

Institutional Trading of Xeris Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its stake in Xeris Biopharma by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock worth $107,000 after purchasing an additional 2,954 shares in the last quarter. R Squared Ltd raised its holdings in shares of Xeris Biopharma by 27.7% in the 1st quarter. R Squared Ltd now owns 15,730 shares of the company’s stock valued at $86,000 after buying an additional 3,410 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Xeris Biopharma by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock worth $273,000 after acquiring an additional 3,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Xeris Biopharma by 31.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock worth $55,000 after acquiring an additional 3,847 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC boosted its holdings in Xeris Biopharma by 6.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock valued at $227,000 after acquiring an additional 3,900 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.